- The shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) have received a $36 price target from H.C. Wainwright. These are the details.
The shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) have received a $36 price target from H.C. Wainwright. And H.C. Wainwright analyst Andrew Fein is maintaining a “Buy” rating on the shares.
Fein adjusted the rating while noting that the FDA’s view on pimavanserin in Alzheimer’s disease psychosis in a recent briefing document does not aggressively turn Acadia’s rationale down. And this gives ACADIA a window of opportunity to argue in favor of approval of pimavanserin in ADP. Plus ACADIA does not believe the FDA has changed its position from its earlier views.
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.
